The antisens drug Ionis is being evaluated in a clinic started through a researcher in patients with COVID-19 in Brazil

IONIS-PKK-LRx is designed to inhibit bradyzine signaling by preventing the synthesis of precalycrein (PKK), a precursor to the enzyme calicrein, which deals with the formation of bradycycin, a protein that promotes inflammation and dilates blood vessels. evidence that pulmonary edema (fluid in the lungs) and related morbidities in severe COVID-19, such as respiratory misery syndrome, are partly due to deregulation of bradycin signaling, called bradycin typhoon. this typhoon of bradycin may potentially be the number of severe cases of COVID-19 in Brazil.

Leave a Comment

Your email address will not be published. Required fields are marked *